Gilead Sciences Inc said its elvitegravir, a component of the company's important four-drug Quad HIV treatment currently awaiting an approval decision, demonstrated similar efficacy and tolerability to Isentress in difficult-to-treat patients. In the two-year late-stage clinical trial, elvitegravir met the primary clinical goal of being "non-inferior" to Merck and Co's Isentress, researchers said. Read More